

CURRICULUM VITAE

Lisa J. Wood PhD RN

Work Address: Oregon Health & Science University
School of Nursing
Mail code: SNORD
3455 SW US Veterans Hospital Road
Portland, OR 97239-2941
(503) 494-3859
woodl@ohsu.edu

Professional Licensure: Oregon License # 201142628RN

Professional Memberships
Oregon Nurses Association

Citizenship: USA

Education

1989	BS Medical Microbiology	University of Dundee, Dundee, Scotland, UK
1994	PhD Molecular Biology	MRC Institute of Virology, University of Glasgow, Scotland, UK
2000	BS Nursing	Johns Hopkins University School of Nursing, Baltimore, MD

Academic Positions & Employment

1994-1996	Post-doctoral Research Fellow, Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD.
1999-2000	Clinical Nurse Associate, The Johns Hopkins University School of Nursing, Wald Community Nursing Center, Baltimore, MD
1996-2001	Post-doctoral Research Fellow, Department of Pediatric Hematology, The Johns Hopkins University School of Medicine, Baltimore, MD
2001-2003	Senior Research Associate, Hematology/Oncology Leukemia Program, Oregon Cancer Institute, Oregon Health & Science University, Portland, OR

2003-present	Assistant Professor, Oregon Health & Science University, School of Nursing, Portland, OR
2003- present	Assistant Professor, Oregon Health & Science University Knight Cancer Institute, Portland, OR
2007-Present	Assistant Professor, Oregon Health & Science University, School of Medicine, Department of Radiation Medicine, Portland, OR.
2010- Present	Associate Professor, Oregon Health & Science University, School of Nursing, Portland, OR.
2010- 2012	Chair, Symptom Management: Integrated Learning Community, Oregon Health & Science University School of Nursing, Portland, OR.
2011-Present	Associate Director, John A. <i>Hartford Center</i> of Geriatric <i>Nursing</i> Excellence, Oregon Health & Science University School of Nursing, Portland, OR.

Honors and Awards

1989	First Class Honors in Medical Microbiology
1996	Institutional Nursing Research Service Award from the National Cancer Institute (T32) Johns Hopkins University School of Medicine.
1999	Barry J. Wood Young Investigator of the year Award for Post-Doctoral Research, Johns Hopkins University School of Medicine.
1999	Undergraduate Merit Scholarship, Johns Hopkins University School of Nursing
1999	Provost Undergraduate Research Award, Johns Hopkins University
2000	Nursing Research Award, Johns Hopkins University School of Nursing
2000	Alumni Association Community Service Award, Johns Hopkins University School of Nursing
2000	Sigma Theta Tau, International Honor Society of Nursing

Publications

1. Sauter AD, **Wood LJ**, Wong J, Iordanov M, and Magun BE. Doxorubicin and daunorubicin induce processing and release of interleukin-1 β through activation of the NLRP3 inflammasome. Cancer Biol Ther. 2011 Jun 15;11(12). [Epub ahead of print]
2. Farley S., **Wood LJ** & Iordanov M. An Epidermotypic Model of Interface Dermatitis Reveals Individual Functions of Fas Ligand and Gamma Interferon in Hypergranulosis, Cytoid Body Formation, and Gene Expression. Am. J Dermatopathol. 2011 Mar 11. [Epub ahead of print]

3. Seo JH, **Wood LJ**, Agarwal A, O'Hare T, Elsea CR, Griswold IJ, Deininger MW, Imamoto A, Druker BJ. A specific need for CRKL in p210^{BCR-ABL}-induced transformation of mouse hematopoietic progenitors. Cancer Research, 2010 70:7325-35.
4. Ross RL, Jones KD, Ward RL, **Wood LJ** & Bennett RM. Atypical depression is more common than melancholic in fibromyalgia: an observational cohort study. BMC Musculoskeletal Disorders, 2010 11:120.
5. Ross RL, Jones KD, Bennett RM, Ward RL, Druker BJ, & **Wood LJ**. Preliminary Evidence of Increased Pain and Elevated Cytokines in Fibromyalgia Patients with Defective Growth Hormone Response to Exercise. The Open Immunology Journal, 2010, (3), 9-18.
6. Tyner JW, Bumm TG, Deininger J, **Wood L**, Aichberger KJ, Loriaux MM, Druker BJ, , Burns CJ, Fantino E, Deininger MW. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative disorder. Blood, 2010 Apr 12 (Epub ahead of print).
7. Hillion J., **Wood LJ**, Mukherjee M., Bhattacharya R., di Cello F, Kowalski J., Elbahloul O., Segal J., Poirier J., Rudin C., Dhara S., Belton B., Joseph B., Zucker S., and Resar L.M. Up-regulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large cell lung cancer. Molecular Cancer Research, 2009, (7), 1803-12.
8. **Wood LJ**, Winters-Stone K, Nail LM. Does muscle-derived interleukin-6 mediate some of the beneficial effects of exercise on cancer treatment related fatigue? Oncology Nursing Forum. 2009, 36(5):519-24.
9. Elsea CR, Roberts D, Errington DM, Druker BJ, & **Wood LJ**. Inhibition of p38 MAPK suppresses inflammatory cytokine induction by etoposide, 5-fluorouracil, and doxorubicin without affecting tumoricidal activity. PLoS ONE 2008, 3(6):e2355.
10. Di Cello F, Hillion J, Hristov A, **Wood LJ**, Mukherjee M, Schuldenfrei A, Kowalski J, Bhattacharya R, Ashfaq R, and Resar LMS. HMGA2 participates in neoplastic transformation in human lung cancer. Molecular Cancer Research 2008, 6(5):743-50.
11. Ross AM, Hurn P, Perrin N, **Wood LJ**, Carlini W, Potempa K. Evidence of the Peripheral Inflammatory Response in Transient Ischemic Attack Patients. Journal of Stroke and Cerebrovascular Disease 2007, 16(5):203-7
12. Bumm TGP, Elsea CR, Corbin AS, Loriaux M, Sherbenou D, **Wood LJ**, Deininger J, Silver RT, Druker BJ & Deininger MWN. Characterization of Murine JAK2^{V617F}-Positive Myeloproliferative Disease. Cancer Research, 2006; 66: 11156-11165.
13. Griswold IJ, Bumm T, O'Hare T, Corbin AS, Stoffregen E, Moseson E, **Wood LJ**, Druker BJ and Deininger MW. Kinase domain mutants of BCR-ABL: altered transformation potency irrespective of sensitivity to imatinib. Molecular & Cellular Biology, 2006, 26:6082-93.
14. **Wood LJ**, Nail LM, Glister A, Winters KA & Elsea CR. Cancer Chemotherapy Related Symptoms: Evidence to Suggest a Role for Pro-Inflammatory Cytokines. Oncology Nursing Forum, 2006; 33:535-542.

15. **Wood LJ**, Nail LM, Perrin NA, Elsea CR, Fischer A, & Druker BJ. The cancer chemotherapy drug etoposide (VP-16) induces pro-inflammatory cytokine production and sickness behavior-like symptoms in a mouse model of cancer chemotherapy related symptoms. Biological Research for Nursing, 2006; 8:157-169.
16. Xu Y, Bhattacharya R, Tesfaye A, Felder T, **Wood LJ**, Huso D, Resar, LMS. Transgenic mice overexpressing *HMG-I* in lymphoid tissue develop lymphoid hyperplasia and malignancy. Cancer Research; 2004, 64: 3371-3375.
17. Dinulescu D, **Wood LJ**, Loriaux M, Shen L, Corless CL, Jauron-Mills L, Gross AL, Ren R, Deininger MW, Druker BJ. C-CBL is not required for leukemia induction by Bcr-Abl in mice. Oncogene 2003; 22:8852-60.
18. **Wood LJ**, Mukherjee M, Dolde CE, Xu Y, Maher JF, Bunton TE, Williams JB, Resar LM. *HMG-I/Y*, a new c-Myc target gene and potential oncogene. Mol. Cell Biol. 2000; 20:5490-502.
19. **Wood, LJ**, Maher JF, Bunton TE, Resar LM. The Oncogenic properties of the HMGI gene family. Cancer Research 2000, 60:4256-61.
20. **Wood LJ**, Baxter MK, Plafker SM, Gibson W. Human cytomegalovirus capsid assembly protein precursor interacts with itself and with the major capsid protein through two different domains. J. Virology 1997;71:179-190.

Research Grants

ACTIVE

(Wood/ Hill, MPI)

7/1/11-6/30/13

Department of Defense Breast Cancer Research Program, Collaborative Idea Award

Cytokine response to subclinical cytomegalovirus reactivation as a cause of severe fatigue in women undergoing chemotherapy for breast cancer. The purpose of this grant is to examine the relationship between cytomegalovirus (CMV) reactivation and fatigue in women undergoing cytotoxic chemotherapy for breast cancer.

(Wood, PI)

9/28/10-6/30/15

5R01NR012479-02, The National Institute for Nursing Research

Mechanisms of Cancer Treatment Related Symptoms.

The purpose of this grant is to use both clinical and pre-clinical approaches to understanding the role of inflammatory cytokines and chemokines in cancer treatment related symptoms.

(Iordanov PI)

9/15/10-6/30/14

1R01GM089859 , National Institute of General Medical Sciences.

Elucidating the FAS-activated inflammation signaling complex (FISC)

The purpose of this grant is to elucidate the mechanisms of non-apoptotic pro-inflammatory signaling through Fas ligand (FasL/TNSF6) and its receptor Fas/TNFRSF6.

Role: Co-Investigator

(Winters-Stone/Wood, Multiple PI)

2/1/12-8/31/13

1R21CA164661-01, National Cancer Institute

Influence of physical exercise on inflammatory biomarkers and adiposity in cancer survivors.

The purpose of this grant is to determine whether physical exercise impacts serum markers of cancer recurrence in cancer survivors post-treatment.

GRANTS SUBMITTED & PENDING

(Wood/ Magun MPI)

7/1/12 – 6/30/16

1R01NR013171-01, National Institute of Nursing Research

Targeting IL-1beta as a strategy for symptom control in cancer. The purpose of this 4-year study is to determine whether mechanistically distinct cytotoxic chemotherapeutic agents trigger cancer treatment related symptoms because they share a common ability to activate the IL-1 signaling/NLRP3 inflammasome pathway. Reviewed February 2012: priority score 16 (4th percentile)

COMPLETED GRANTS

(Wood, Jones MPI)

9/1/2009-8/31/2011

1R21AR056751-01, The National Institute of Arthritis & Musculoskeletal and Skin

Diseases. The neuroendocrine & inflammatory cytokine response to exercise in fibromyalgia.

The purpose of this grant is to determine whether systemic inflammation underlies the increased fatigue and pain in people with fibromyalgia following strenuous exercise.

(Wood, PI)

7/1/2007-6/30/2010

R21: The National Institute of Nursing Research 1R21NR010363-02

The Role of Inflammatory Cytokines in Fatigue Associated with External Beam Radiation Therapy for Prostate Cancer. Using a translational research approach to determine the relationship between treatment-related inflammatory cytokine production and treatment related fatigue.

(Wood, PI)

7/1/2005 – 6/30/2010

American Cancer Society RSGPB-05-212-01-CPPB

The Role of Cytokine Deregulation in Cancer Treatment Related Fatigue
Our long-range goal of this program of research is to develop targeted therapies to effectively treat and manage cancer related symptoms, including fatigue. To this end, we have developed an innovative murine model to experimentally evaluate the associations among cancer and its treatment.

(Wood, PI)

3/1/2007-2/28/2010

Oregon Clinical & Translational Research Institute

The Role of IL-6 in Breast Cancer Treatment Associated Loss of Lean Body Mass. Our preclinical data implicates IL-6 in the loss of lean body mass in women undergoing systemic antineoplastic chemotherapy for breast cancer. The purpose of this one-year study is to examine this relationship in a clinical setting.

(Wood, PI)

2/1/2007-12/31/2009

Collins Medical Trust Foundation

The Role of Interleukin-6 in Fatigue associated with Muscle damaging Exercise

The purpose of this study is to generate clinical data to support a role for interleukin-6 in the loss of muscle wasting in women undergoing adjuvant breast cancer chemotherapy. Our findings from this clinical study will shape our pre-clinical studies funded by the ACS grant. The data generated from both the clinical and pre-clinical studies which will run in parallel will form the basis of future grant applications.

(Wood, PI)

9/13/05 – 9/12/06

OHSU - Vertex Pharmaceuticals

Moderation of Cancer Related Symptoms Using p38 MAPK or Dual p38 MPK/JNK Inhibitors

We propose a novel and innovative use for inhibitors of the p38 and JNK signaling pathways in moderating the symptoms associated with cancer and its treatment. The long-range goal of this line of research is to effectively treat and manage cancer related symptoms.

(Nail, PI)

9/1/03 - 8/31/04

National Institute of Nursing Research 1P20 NR07807-03

Chemotherapy Associated Fatigue and Cytokine Deregulation in Mice

To determine the role of cancer chemotherapy in fatigue and cytokine deregulation in mice.

Role: Subproject Principal Investigator

Presentations at Professional Meetings

1. L.J. Wood, J.Wong, T. Engstrom Jr., K. Kelley-Howard, E. Magun and B. Magun. Cytotoxic cancer chemotherapeutic agents induce IL-1 β production by immune cells. Western Institutes of Nursing Annual Communicating Nursing Research Conference, April 18–21, 2012, Portland, OR
2. F. A. Siddiqui, S. K. Chennupati, T. L. McDonald, C. R. Thomas, A.Y. Hung, L.J. Wood. TNF- α deficiency as protection against sickness behavior related to external beam radiation of the pelvis in mice. Genitourinary Cancers Symposium February 2-4, 2012, San Francisco, CA.
3. G.P. Keller, L.M. Nail, K.S. Lyons, L.J. Wood, D. Rohlman. Measurement Issues in the Study of Risk Factors for Deficits in Neuropsychological Function Related to Chemotherapy. The Nursing Honor Society, Sigma Theta Tau International, 41st Biennial Convention, 29th Oct-2nd Nov., 2011, Grapevine, Texas, USA.
4. F. A. Siddiqui, S. K. Chennupati, T. L. McDonald, C. R. Thomas, A. Hung, L. Wood. A Prospective Phase II Study Evaluating the Relationship of Fatigue and Plasma Inflammatory Cytokine Levels In Prostate Cancer (PC) Patients Undergoing External Beam Radiation Therapy (EBRT). American Society for Therapeutic Radiation Oncology, 53rd Annual Meeting, October 2-6, 2011 - Miami Beach Convention Center, Miami Beach, Fla.

5. F. A. Siddiqui, S. K. Chennupati, T. L. McDonald, C. R. Thomas, A.Y. Hung, L.J. Wood TNF- α deficiency does not protect mice from sickness behavior related to external beam radiation of the pelvis. 97th Annual Meeting of the Radiological Society of North America, November 27-December 2, Chicago, Illinois.
6. Sauter AD, Wood LJ, Wong J, Jordanov M, and Magun BE. Doxorubicin and daunorubicin induce processing and release of interleukin-1 β through activation of the NLRP3 inflammasome. NINR/NCI Joint Conference *Symptom Mechanisms, Measurement and Management* Conference. May 12th, 2011, Bethesda, Washington DC.
7. L.J. Wood, invited speaker- Neuroendocrine and immune dysfunction as a cause of persistent cancer treatment related symptoms . At Long Term Effects of Cancer Treatment: Surveillance, mechanisms, and interventions. June 10, 2011, Fred Hutchinson Cancer Research Center, Arnold Bldg., Seattle, Washington.
8. L. J. Wood, invited speaker- The relationship between inflammatory cytokine response to radiation therapy and cancer treatment related fatigue. Pacific North West Prostate Cancer SPORE Advisory Board Meeting, Fred Hutchinson Cancer Research Center, Seattle, WA, November 9-10, 2009.
9. L. J. Wood, Symposium Speaker - Animal Models of Cancer and Cancer Treatment Symptoms. The 10th Annual Conference of Cancer Nursing Research, Orlando, FL, February 12-14, 2009.
10. L.J. Wood, T. McDonald, D. Roberts, X. Han, A. Hung and C.R. Thomas Jr. Pelvic Irradiation Induces a Systemic TNF- α Response and Sickness Syndrome in Mice: Implications for Cancer Treatment Related Fatigue. International Journal of Radiation Oncology Biology Physics Volume 72, Issue 1, Supplement 1, 1 September 2008, Pages S701-S702 Proceedings of the American Society for Therapeutic Radiology and Oncology 50th Annual Meeting, American Society for Therapeutic Radiology and Oncology 50th Annual Meeting.
11. T. L. McDonald, A. Hung, D. A. Roberts, M. Loriaux, B. Druker, C. R. Thomas, L. J. Wood. Determining the relationship between inflammatory cytokine response to radiation therapy and cancer treatment related fatigue, 2008 Genitourinary Cancers Symposium February 14–16, 2007, in San Francisco, California
12. Collin R. Elsea, Daniel Roberts, Nancy A. Perrin, Lillian M. Nail, Charles R. Thomas Jr., Brian J. Druker, Lisa J. Wood. Induction of interleukin-6 by adjuvant breast cancer treatment in mice promotes loss of lean body mass via down-regulation of insulin-like growth factor I. The 2007 American Association of Cancer Research Annual Meeting, Los Angeles, CA, April 14-18, 2007
13. David M. Errington, Collin R. Elsea, Daniel Roberts, Charles R. Thomas Jr., Brian J. Druker, & Lisa J. Wood. Development of a mouse model to determine the role of IL-1 β ,

TNF- α , and IL-6 in fatigue associated with localized external beam radiation (EBRT) for prostate cancer. The 2007 American Association of Cancer Research Annual Meeting, Los Angeles, CA, April 14-18, 2007

14. Collin R. Elsea, Daniel Roberts, Nancy A. Perrin, Lillian M. Nail, Charles R. Thomas Jr., Brian J. Druker, Lisa J. Wood. Induction of interleukin-6 by adjuvant breast cancer treatment in mice promotes loss of lean body mass via down-regulation of insulin-like growth factor I: the role of AMP-activated protein kinase (AMPK). The 7th AACR-JCA Joint Conference, Waikoloa, Hawaii, January 21-25, 2007.
15. Wood LJ, Nail LM, Elsea CR, Fischer A, Perrin NA, & Druker BJ. The cancer chemotherapy drug etoposide (VP-16) induces pro-inflammatory cytokine production and sickness behavior-like symptoms in a mouse model of cancer chemotherapy related symptoms. The 2006 American Association of Cancer Research Annual Meeting, Washington, DC, April 2-6, 2006.
16. M. MacPartlin, T. O'Hare, T. Bumm, V. Goss, K. Lee, A. Corbin, E.A. Stoffregen, C. Smith, K. Johnson, E. Moseson, I. Griswold, L. Wood, R. Polakiewicz, Brian J. Druker, and Michael W.N. Deininger. Kinase Domain Mutants of Bcr-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to Imatinib. Blood (American Society for Hematology Annual Meeting Abstracts), Nov 2006; 108: 4796.
17. Thomas G.P. Bumm, Collin Elsea, Lisa G. Wood, Daniel W. Sherbenou, Ian J. Griswold, Marc Loriaux, Brian J. Druker, and Michael W. Deininger. JAK2 V617F Mutation Induces a Myeloproliferative Disorder in Mice. Blood (The American Society for Hematology Annual Meeting Abstracts), Nov 2005; 106: 376.
18. Thomas G.P. Bumm, Jonathan VanDyke, Marc Loriaux, Carolyn Gendron, Lisa J. Wood, Brian J. Druker, and Michael W.N. Deininger. TNF- α Plays a Crucial Role in the JAK2-V617F Induced Myeloproliferative Disorder. Blood (American Society of Hematology Annual Meeting Abstracts), Nov 2007; 110: 675.
19. Shadmehr Demehri, Thomas O'Hare, Lisa J. Wood, Marc Loriaux, Brian J. Druker, and Michael W. Deininger. BCR-ABL Lacking the Pleckstrin Homology (PH) Domain of BCR Induces a More Aggressive Leukemia Than P210^{BCR-ABL} in a Murine Model of CML. Blood (American Society of Hematology Annual Meeting Abstracts), Nov 2004; 104: 2564.
20. Wood LJ, Nail LM, Elsea CR, Fischer A, Perrin NA, & Druker BJ. The cancer chemotherapy drug etoposide (VP-16) induces pro-inflammatory cytokine production and sickness behavior-like symptoms in a mouse model of cancer chemotherapy related symptoms. Mechanisms & Treatment of Cancer-Related Symptoms. Houston, Texas; Sept. 10-12, 2005.

21. Wood LJ, Nail LM, Elsea CR, Fischer A, Perrin NA, & Druker BJ. Development of a murine model to determine the role of pro-inflammatory cytokines in cancer related symptoms. The 8th National Conference on Cancer Nursing Research. Fort Lauderdale, Florida; Feb 3-5, 2005.
22. Wood LJ & Nail LM. The effect of cancer chemotherapy on voluntary wheel-running activity in mice. Mechanisms & Treatment of Cancer-Related Symptoms. Houston, Texas; Feb 20-22, 2004.
23. Xu Y, Huso D, Wood LJ, Mukherjee M, Kaur H, Resar LMS. HMG-I/Y: A c-Myc target gene and oncogene involved in lymphoid malignancy. Third International Workshop on the HMGA Proteins in Cell Transformation and Differentiation Naples, Italy; May 24, 2002.
24. Mukherjee M, Wood LJ, Dolde CE, Cho C, and Resar LMS. The role of HMG-I/Y in the transformed phenotype of human lung and breast cancer. Foundation for Advanced Cancer Studies, Seventeenth Annual Meeting on Oncogenes, Hood College, Frederick, MD. 2001.
25. Wood LJ, Xu Y, and Resar LMS. HMG-I/Y: A c-Myc target gene and putative oncogene involved in lymphoid malignancy. 2001 *J Pediatr Hematol Oncol* 23: A3. and *Pediatr Res*.
26. Mukherjee M, Xu Y, Wood LJ, Dolde CE, Resar LMS. (2000, June 22-25th). HMG-I/Y: A c-Myc Target Gene Down-regulated in Myc-deficient Fibroblasts. Poster presentation at the Foundation for Advanced Cancer Studies, Sixteenth Annual Meeting on Oncogenes, The Salk Institute, La Jolla, San Diego, CA
27. Mukherjee M, Wood LJ, & Resar LMS.(2000, June 22-25). The role of the HMG-I/Y in Human lung cancer. Poster presentation at the Foundation for Advanced Cancer Studies Sixteenth Annual Meeting on Oncogenes, The Salk Institute, La Jolla, San Diego, CA.
28. Wood, LJ, Dolde CE, Maher JF, Bunton TE, Williams JB, Resar, LMS. (1999, 22-27th June). HMG-I/Y, a new c-Myc target gene and potential oncogene. Paper presentation at the Foundation for Advanced Cancer Studies, Fifteenth Annual Meeting on Oncogenes, Hood College, Frederick, MD.
29. Wood, LJ, Dolde CE, Maher JF, Bunton TE, Williams JB, Resar, LMS. (1999, April 17th). HMG-I/Y, a new c-Myc target gene and potential oncogene. Poster presentation at the Young Investigator of the Year Awards, Johns Hopkins University School of Medicine, Baltimore, MD.
30. Wood, LJ., Bunton TE., Maher JF, Resar LMS. (1998, June 24-27). The oncogenic properties of the HMGI family of chromosomal proteins. Paper presentation at the Foundation for Advanced Cancer Studies, Fourteenth Annual Meeting on Oncogenes, The Salk Institute, La Jolla, San Diego, CA.

31. Wood LJ, Maity A, Williams JB, Resar LMS (1997, June 18-21). HMG-I/Y: A new c-Myc target gene up-regulated in cell growth and neoplastic transformation. Poster presentation at the Foundation for Advanced Cancer Studies, Thirteenth Annual Meeting on Oncogenes, Hood College, Frederick, MD.
32. L.M.S. Resar, Maity, A., Wood LJ, and J.B. Williams. Regulation of the delayed-early gene HMG-I/Y by c-Myc and Max. The American Society for Hematology, 38th Annual Meeting, Orlando, Fl. Blood 1997, (Suppl. 1). 88:556a.

Courses Taught

2005-2006

NURS607BB: Predissertation Seminar

This doctoral seminar provides a forum for scholarly exchange to facilitate the synthesis and integration of doctoral course work and experience in the conduct of research. The emphasis is on the development of a dissertation research proposal. First year students will have the opportunity to identify faculty mentors, to develop and refine specific aims, and to review the literature for drafting a background and significance section. Second- and third-year students will be able to refine their work from the first year and begin to develop the methods for their dissertation work. The seminar will provide all students with the opportunity for the review and critique of scholarly work in process. (1 Credit).

2008

NURS625: Design & Analysis for Intervention in Nursing,

This course focuses on the development and conduct of nursing intervention studies. Experimental and quasi-experimental design in nursing research and the analysis approaches that are commonly used with these designs are emphasized. Special attention will be given to the development and description of independent variables and the selection and measurement of dependent variables. (3 Credits)

2009-Present

NURS230: Clinical Pharmacology I

This course introduces the theoretical background that enables students to provide safe and effective care related to drugs and natural products to persons throughout the lifespan. Students will learn to make selected clinical decisions in the context of nursing regarding using current, reliable sources of information, understanding of pharmacokinetics and pharmacodynamics, developmental physiologic considerations, monitoring and evaluating the effectiveness of drug therapy, teaching persons from diverse populations regarding safe and effective use of drugs and natural products, intervening to increase therapeutic benefits and reduce potential negative effects, and

communicating appropriately with other health professionals regarding drug therapy. Drugs are studied by therapeutic or pharmacological class using an organized framework. (3 Credits)

2009-Present

NURS231: Clinical Pharmacology II.

This sequel to Clinical Pharmacology I continues to provide the theoretical background that enables students to provide safe and effective care related to drugs and natural products to persons throughout the lifespan. Students will learn to make selected clinical decisions regarding using current, reliable sources of information, monitoring and evaluating the effectiveness of drug therapy, teaching persons from diverse populations regarding safe and effective use of drugs and natural products, intervening to increase therapeutic benefits and reduce potential negative effects, and communicating appropriately with other health professionals regarding drug therapy. The course addresses additional classes of drugs and related natural products and physiological conditions (e.g. postpartum depression and schizophrenia) not contained in Clinical Pharmacology I. (3 Credits)

2009-2010

NURS721 Genomics in Healthcare

This course reviews and analyzes genetic influences and determinants affecting the health of individuals, families, and communities. Social, political, legal, and ethical factors will be examined. Application to healthcare practice is stressed. (2 Credits)

2010

NURS607H Special Topics: Biological Measurement in Nursing Research

This seminar is designed to provide an overview of current research on select biological measures relevant to nursing research. The seminar comprises 5 modules: 1) An overview of select topics in molecular genetics and cell biology, 2) Genetic variation: Single nucleotide polymorphisms in health & disease, 3) Epigenetics " Nature or Nurture", 4) Genomics and proteomics: nursing implications for complex disease prevention and management and 5) Animal models: research issues in animal models of human disease. (3 Credits)

Professional Service Activities

Manuscript Reviewer

2006	Manuscript Reviewer for Expert Opinion on Investigational drugs
2006	Manuscript reviewer for British Journal of Cancer.
2007	Manuscript reviewer for Journal of Experimental Therapeutics and Oncology.
2008	Manuscript reviewer for Experimental and Molecular Pathology
2008	Manuscript reviewer for Scandinavian Journal of Medicine and Science in Sports
2008	Manuscript reviewer for European Journal of Pharmacology
2008	Manuscript reviewer for PLoS ONE

2009 Manuscript reviewer for Journal of Inflammation Research
2009-10 Manuscript reviewer, Biological Research for Nursing.
2010 Manuscript reviewer, Integrative Cancer Therapies
2010 Manuscript reviewer Expert Opinion on Pharmacotherapy
2011 Manuscript reviewer for Neuroimmunomodulation.
2011 Manuscript reviewer for Psychoneuroendocrinology.
2011 Manuscript reviewer for Research in Nursing & Health

Research Grant Reviewer

2007 Ad-hoc grant reviewer for the American Society for Clinical Oncology Foundation Grant Program.

2008 Grant reviewer Thrasher Research Fund.

2007-present Medical Research Foundation of Oregon, New Investigator and Early Clinical Investigator Grants.

Faculty Mentoring

2009-present Faculty collaborator, Dr. Beth Darnall PhD, Assistant Professor, Department of Anesthesiology, OHSU School of Medicine. Medical Research Foundation of Oregon funded proposal "*Pain catastrophizing as a cause of systemic inflammation in women*"

2008-2011 Faculty Mentor, Dr. Jennifer Loftis PhD, Associate Professor, Dept. of Psychiatry, Oregon Health & Science University School of Medicine. Veterans Association Career Development Award (CDA-2). *Inflammatory mediators in depression and HCV treatment variability.*

2008 Faculty Mentor for Research Practicum, Dr. Abner Ward MD, Resident, Oregon Health & Science University, SOM Department of Orthopedic Surgery. *The Role of IL-6 in the Fatigue Related to Muscle-Damaging Exercise.*

2007-2010 Faculty Co-Mentor, Dr. Tasha McDonald MD, Resident, Oregon Health & Science University, School of Medicine, Department of Radiation Medicine application to Medical Research Foundation of Oregon- Early Clinical Investigator and Radiological Society of North America award. *The Role of IL-1 β , TNF- α , IL-6 in Prostate Cancer Treatment Related Fatigue.*

Postdoctoral Fellow Mentoring

2011-Present Mentor, Dr. Jessica Thaxton, PhD, Post-doctoral Fellow application to Department of Defense Breast Cancer Research Program, Medical Research Foundation of Oregon- Early Clinical Investigator grant.

- 2008-2011 Mentor, Rebecca Ross NP, PhD. Oregon Health & Science University. NRSA Institutional Research (T32) "Research Training in Individual and Family Symptom Management"
- 2009 Faculty Mentor, Dr. Britta Torgrimson PhD, Post-doctoral Fellow, Oregon Health & Science University, School of Nursing, application to Department of Defense Breast Cancer Research Program.

PhD Student Mentoring

- 2009- Present Faculty Co-Mentor, Kristianna Weymann RN, BSN, MS, 2009, John. A. Hartford Foundation Building Academic Geriatric Nursing Capacity Predoctoral Scholarship. *Characterization of Fatigue Following Stroke*. Oregon Health & Science University.
- 2008- Present PhD Committee Chair, Kris Weymann RN, BSN, MS. *Characterization of fatigue following stroke*. Oregon Health & Science University.
- 2009- Present PhD Committee Member: Ginger Keller RN MS, *Cognitive effects of cancer treatment*. Oregon Health & Science University.
- 2005- Present PhD Committee Member: Dallen NP Ormond, Dissertation Title: *Leptin Induced Left Ventricular Hypertrophy in Obese Children and Adolescents*, Oregon health & Science University.
- 2004-2005 PhD Committee Member: Amy Ross RN, MS, CNS, Dissertation Title: *Evidence of the Acute Phase Response in Transient Ischemic Attack Patients*, Oregon Health & Science University.

Mentored Funded/Pending Research Grants

(Weymann PI)

2/1/12-11/30/14

Ruth L. Kirschstein National Research Service Awards (NRSA).

Association of poststroke fatigue trajectories with cytokine polymorphisms. By shedding light on whether inflammation plays a role in poststroke fatigue, this research supports the development of therapies targeted to reduce symptom burden in stroke survivors. In addition this research will support improved education to stroke survivors and their families about persistent symptoms such as fatigue, which might decrease symptom distress.

Role: Co-Sponsor with Lillian M. Nail

(Thaxton, PI)

1/1/11- 12/31/11

Medical Research Foundation of Oregon- Early Clinical Investigator (ECI).

CMV Infection as a risk factor for persistent CTRF in breast cancer survivors.

Role: Mentor

(Thaxton, PI)

7/1/11-6/30/13

BC103909, The Department of Defense Breast Cancer Research Program Postdoctoral Fellowship Award

Chemotherapy Necessitates Increased Immune Control of Chronic HHVs: A Cause of Persistent Inflammation Enabling Protracted Fatigue in Breast Cancer Survivors.

Role: Mentor

(Darnall PI)

03/01/10-02/28/12

Medical Research Foundation of Oregon

Pain catastrophizing as a cause of systemic inflammation in women.

Role: Collaborator

(McDonald PI)

7/1/07-6/30/08

Medical Research Foundation of Oregon- Early Clinical Investigator (ECI).

The role of IL-1 β , TNF- α and IL-6 in prostate cancer treatment related fatigue.

Role: Mentor

(McDonald PI)

7/1/07-6/30/08

The Radiological Society of North America Research Resident Grant

The role of IL-1 β , TNF- α and IL-6 in prostate cancer treatment related fatigue.

Role: Mentor

Professional Committees

- | | |
|---------------|---|
| 2012- Present | Medical Research Foundation Committee
The Research Committee act as a peer review group for research fund requests to the Dean. Upon approval of the Dean, assist in peer review functions for outside organizations such as the Medical Research Foundation. Advise the Dean on means of improving research activities of faculty and students of the school of Medicine. |
| 2011- Present | OHSU Conflict of Interest in Research Committee |
| 2010- Present | Search committee chair, Biostatistician, Oregon Health & Science University, School of Nursing. |
| 2010 | Search committee member, Director of the Nurse Anesthesia Program, Oregon Health & Science University, School of Nursing. |
| 2011- Present | Member, Oregon Health & Science University, SON, Admissions and Progressions Committee |
| 2010- Present | Chair, Symptom Management Integrative Learning Community (ILC).
Symptoms such as pain, fatigue, changes in cognition, sleep disruption, and depression have a major negative impact on people of all ages. This ILC seeks to bring together faculty who share a common interest in symptom management, measurement and underlying mechanisms (with a |

focus on physiological and genomic) with the aim of integrating knowledge development and dissemination of symptom science across all missions.

- 2007-Present OHSU School of Medicine Research Committee
- 2007-2010 Chair, Oregon Health & Science University, School of Nursing, PhD Curriculum Committee
- 2005-2007 Member, Oregon Health & Science University, School of Nursing, PhD Curriculum Committee
- 2005-2006 Member, School of Nursing Research Council

Community Service Activities

- 2009 Consultant: Pigs for Peace, Great Lakes restoration- “Building the Peace” <http://www.pigsforpeace.org/>
- 2011 Task force to develop the Oregon Health & Science University, School of Nursing, *Undergraduate Honors Program in Gerontological Nursing* funded by a Hearst Foundation Education Grant.
- 2011-Present Co-Director, Oregon Health & Science University Healthy Aging Alliance.
- 2009 Member of the development group of the workshop series *Critical Issues in Central Sensitivity: Bench, Translational and Clinical Evidence*